Entasis Therapeutics Holdings Inc. announced that David Meek has been appointed as Chairman of the Board of Directors, effective immediately. Mr. Meek will succeed Nicholas Galakatos, who will continue to serve as a director on the Board. Mr. Meek has over 25 years of experience in the healthcare industry where he has held various global executive positions at major pharmaceutical and biotechnology companies. He is currently the Chief Executive Officer and Board member of Ipsen Pharmaceuticals. He also serves on the Board of Directors of uniQure, PhRMA, and EFPIA.